tumor immunogenicity

Show results for

Unknown (2207)
Genomics (378)
Transcriptomics (227)
Proteomics (58)
Clinical (29)
Other (13)
Methylation profiling (4)
Models (1)
Genomic (1)

Organisms

Mus musculus (159)
Homo sapiens (147)
Andropogon gerardi (43)
Bacteria (43)
Canis lupus familiaris (43)
Cnidaria (43)
Eukaryota (43)
Fasciola (43)
Hepatitis B virus (43)
Human alphaherpesvirus 1 strain 17 (43)
Human alphaherpesvirus 1 strain KOS (43)
Human betaherpesvirus 5 (43)
Human herpesvirus 2 strain 186 (43)
Madurella mycetomatis (43)
Mesocricetus auratus (43)
Miscanthus x giganteus (43)
Mus musculus (43)
Orthoflavivirus (43)
Panicum virgatum (43)
Platyhelminthes (43)
Pseudomonas aeruginosa AES-1R (43)
Rattus norvegicus (43)
Rattus rattus (43)
Rhodococcus jostii RHA1 (43)
Mycobacterium tuberculosis (2)
Mycobacterium tuberculosis variant bovis BCG str. Pasteur 1173P2 (1)
Macaca mulatta (1)
Salmonella enterica subsp. enterica serovar Typhimurium (1)
synthetic construct (1)
Rattus rattus (1)

Organisms

Mus musculus (127)
Homo sapiens (119)
Salmonella enterica subsp. enterica serovar Typhimurium (1)
Salmonella enterica subsp. enterica (1)

Repository

ENA (336)
geo (251)
pride (43)
biostudies-arrayexpress (27)
EGA (9)
iProX (7)
MassIVE (7)
BioModels (1)
dbGaP (1)

Tissue

Cell culture (13)
Skin (5)
B cell (4)
Epithelial cell (4)
Permanent cell line cell (4)
Blood (3)
Lung (3)
Malignant cell (3)
Bone marrow (2)
Colon (2)
Dendritic cell (2)
Kidney (2)
Melanocyte (2)
Ovary (2)
Blood cell (1)
Breast (1)
Breast cancer cell (1)
Breast cancer cell line (1)
Central nervous system (1)
Fibroblast (1)
Glioma cell (1)
Hepatocyte (1)
Liver (1)
Melanoma cell line (1)
Monocyte (1)
Mucosal melanoma cell (1)
Palate (1)
Primary cell (1)
Renal cell carcinoma cell (1)
Tongue (1)

Disease

Colorectal Neoplasms (11)
Carcinoma (4)
Malignant neoplasm of ovary (4)
Neoplasms (3)
Melanoma (3)
Non-small cell lung carcinoma (3)
Breast cancer (2)
Colon cancer (2)
Renal cell carcinoma (2)
Renal clear cell carcinoma (2)
Neoplasms, Glandular and Epithelial (1)
Digestive System Neoplasms (1)
Colorectal cancer, Gastric cancer, Esophageal cancer, Biliary tract cancer, Pancreatic cancer, and Other Solid cancer (1)
Crohn Disease (1)
Carcinoma, Renal Cell (1)
Carcinoma, Squamous Cell (1)
Inflammatory Bowel Diseases (1)
Pancreatic Neoplasms (1)
Glioblastoma (1)
Stomach Neoplasms (1)
Lung Neoplasms (1)
Acute leukemia (1)
Chronic lymphocytic leukemia (1)
Endometrial cancer (1)
Head and neck cancer (1)
Head and neck squamous cell carcinoma (1)
Hepatitis B (1)
Hepatocellular carcinoma (1)
Lung cancer (1)
Lymphoma (1)

Technology Type

Mass Spectrometry (43)
Shotgun proteomics (16)
Data-dependent acquisition (11)
Affinity purification coupled with mass spectrometry proteomics (10)
Immunopeptidomics (8)
Bottom-up proteomics (6)
Data-independent acquisition (2)
SRM/MRM (1)
SWATH MS (1)
Top-down proteomics (1)

Instrument Platform

Illumina NovaSeq 6000 (2)
Illumina HiSeq 2000 (2)
Orbitrap Exploris 480 (2)
Illumina HiSeq X (1)
Illumina HiSeq 2500 (1)
NextSeq 500 (1)
LTQ Orbitrap XL (1)
Orbitrap Eclipse (1)
Orbitrap Fusion Lumos (1)
Q Exactive (1)
Q Exactive Plus (1)

Publication Date

2024 (71)
2026 (71)
2025 (63)
2023 (40)
2022 (30)
2021 (16)
2014 (9)
2020 (8)
2019 (6)
2016 (3)
2015 (3)
2013 (3)
2018 (3)
2012 (2)
2011 (2)
2009 (2)
2017 (2)
2010 (1)
2008 (1)

UNIPROT ID/AC

C4NUM1 (1)
A2RSY7 (1)
Q9ES17 (1)

First Public Date

2026 (78)
2024 (78)
2025 (53)
2023 (36)
2022 (36)
2021 (20)
2020 (13)
2019 (6)
2017 (6)
2018 (4)
2014 (4)
2016 (1)
2015 (1)

Modelling Approach

Ordinary differential equation model (1)

Study status

Recruiting (11)
Completed (11)
Active, not recruiting (2)
Not provided (2)
Terminated (1)
Withdrawn (1)
Not yet recruiting (1)

Lab affiliation

Dept. Oncology-Pathology, Scilifelab, Karolinska Institutet, Sweden (2)
1 Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands 2 Netherlands Proteomics Centre, Padualaan 8, 3584 CH Utrecht, The Netherlands (1)
1 Children’s Cancer and Blood Foundation Laboratories, Departments of Pediatrics, and Cell and Developmental Biology, Drukier Institute for Children’s Health, Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA (1)
1 German Cancer Consortium of Translational Cancer Research (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany 2 IIIrd Medical Department, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany 3 Center for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Munich, Germany (1)
1. Department of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital Tübingen, Germany 2. Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen, Germany 3. Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, University Hospital Tübingen, Germany 4. German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), partner site Tübingen, Germany (1)
Cancer Biology Department, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Cell Biology, Harvard Medical School, Boston, MA, USA. (1)
Cell Death Investigation and Therapy (CDIT) Laboratory, Anatomy and Embryology Unit, Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium (1)
Department of Biochemistry and Molecular Biology, Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton 3800 Victoria, Australia. (1)
Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, United States (1)
Department of Biological Engineering, Massachusetts Institute of Technology & Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (1)
Department of Gynecology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University，Shanghai，China (1)
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (1)
Department of Immunology, Interfaculty Institute for Cell Biology, Tübingen, Germany (1)
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA (1)
Department of Otorhinolaryngology and Head & Neck Surgery, University Medical Center Ulm, Head and Neck Cancer Center of the Comprehensive Cancer Center Ulm, Ulm, Germany (1)
Department of Pathology, Dalhousie University (1)
Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany (1)
Department of Pharmacology and Chemical Biology, Emory University, USA (1)
Department of oncology UNIL CHUV Ludwig Institute for Cancer Research Lausanne Office B25A/04/94 Rue du Bugnon 25a, CH-1005 Lausanne (1)
Division of Immunotherapy and Immunoprevention, German Cancer Research Center (DKFZ), Heidelberg, Germany (1)
Experimental Systems Immunology, Max Planck Institute of Biochemistry, Martinsried, Germany (1)
Faculty of Biology, Technion - Israel Institute of Technology (1)
Francis Impens, VIB-UGent Center for Medical Biotechnology, Ghent, Belgium.Department of Biomolecular Medicine, Ghent, Belgium. VIB Proteomics Core, Ghent, Belgium (1)
Head of System Biology Lab. at Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency (1)
IRIC-Université de Montréal (1)
Institut Curie, Université Paris Sciences et Lettres, INSERM U932, 75005 Paris, France. (1)
Institute for Research in Biomedicine (IRB), Barcelona Institute of Science and Technology (BIST), Barcelona 08028, Spain; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona 08010, Spain (1)
Institute for Research in Immunology and Cancer, Department of Biochemistry, Department of Chemistry, Université de Montréal, Québec, Canada H3T 1J4 (1)
Institute of Biochemistry II, Goethe University Frankfurt, Medical School, 60590 Frankfurt, Germany (1)
Institute of Microbiology, Department of Microbial Proteomics, Center for Functional Genomics of Microbes, University of Greifswald, 17489 Greifswald, Germany (1)

Keyword

Urothelial Cancer (3)
Renal Cell Cancer (3)
Gastroesophageal Junction Cancer (3)
Ipilimumab (3)
Hepatocellular/Liver Cancer (2)
Safety (2)
Triple Negative Breast Cancer (2)
Nivolumab (2)
Irinotecan (2)
Antibodies (2)
Immunotherapy (2)
Leucovorin (2)
Bevacizumab (2)
Fluorouracil (2)
Cetuximab (2)
Oxaliplatin (2)
Esophageal Cancer (EC) (1)
Pancreatic Cancer (PC) (1)
HuA33 (1)
Dendritic cells (1)
Nous-209 (1)
Biosimilars (1)
Anti-TNF (1)
Shared neoantigen (1)
GRT-C903 (1)
GRT-R904 (1)
Gastric Cancer (GC) (1)
DUET-4 (1)
Lymphocyte-activation gene 3 (LAG3) (1)
Cytotoxic T-lymphocyte-associated protein 4 (CTLA4) (1)

IsPrivate

False (1)

Submitter Keywords

Immuno-oncology (1)

Classification

bacteria (2)

Study type

Interventional (27)
Transcription profiling by array (19)
RNA-seq of coding RNA (6)
DNA-seq (1)
Proteomic profiling by array (1)
Observational patient registry (1)
Observational (1)

Release Date

2022 (315)
2025 (280)
2023 (278)
2021 (255)
2024 (245)
2020 (179)
2019 (123)
2018 (107)
2017 (84)
2016 (73)
2015 (60)
2014 (53)
2026 (43)
2012 (37)
2013 (24)
2011 (21)
2010 (17)
2009 (14)
2008 (8)
2007 (5)
2006 (3)
2005 (2)
2004 (2)
2001 (2)
1998 (2)
2003 (1)
2002 (1)

Location

United States (14)
China (6)
Italy (5)
Spain (5)
Netherlands (3)
United Kingdom (3)
South Korea (2)
Germany (2)
Belgium (2)
Georgia (1)
Taiwan (1)
Ukraine (1)
Portugal (1)
Denmark (1)
Turkey (1)
Poland (1)
Israel (1)
Czechia (1)
Canada (1)
Switzerland (1)
Japan (1)
France (1)

Previous page
1 / 292
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 292
Next page

Sort by:

Relevance

Page size

Inhibiting tumor cell-intrinsic UBA6 by inosine augments tumor immunogenicity

PRJNA864795 | ENA

Immunogenicity of non-canonical HLA-I tumor ligands identified through proteogenomics

Tumor antigens are central to antitumor immunity. Recent evidence suggests that peptides from non-canonical (nonC) aberrantly translated proteins can be presented on HLA-I by tumor cells. Here, we investigated the presentation and immunogenicity of nonC antigens across different cancer types to bett...

ORGANISM(S): Homo sapiens (Human)

2023-02-03 | PXD036856 | Pride

Human Non-canonical hla-i ligands

Epigenetic Silencing by SETDB1 Suppresses Tumor-cell Intrinsic Immunogenicity

Griffin GK, Wu J, Iracheta-Vellve A, Patti JC, Hsu J, Davis T, Dele-Oni D, Du PP, Halawi A, Ishizuka JJ, Kim S, Klaeger S, Knudsen NH, Miller BC, Nguyen T, Olander K, Papanastasiou M, Rachimi S, Robitschek EJ, Schneider EM, Yeary M, Zimmer M, Jaffe JD, Carr SA, Doench JG, Haining WN, Yates KB, Mangu...

ORGANISM(S): Mus Musculus (ncbitaxon:10090)

2020-12-11 | MSV000086580 | MassIVE

Selective Mitochondrial Respiratory Complex I Subunit Deficiency Causes Tumor Immunogenicity

PRJNA1098002 | ENA

ExomeSeq Neoantigen Immunogenicity Landscapes

Immune checkpoint blockade (ICB) therapy is a cornerstone of oncologic treatment for patients with advanced stage non-small cell lung cancer (NSCLC) and other malignancies. Neoantigen immunoediting drives ICB efficacy, yet the fundamental physiochemical characteristics of neoantigens and how neoant...

EGAS00001007508 | EGA

RNASeq Neoantigen Immunogenicity Landscape

EGAS00001007509 | EGA

Targeting the Atf7ip-Setdb1 complex augments anti-tumor immunity by boosting tumor immunogenicity

PRJNA744222 | ENA

Epigenetic Silencing by SETDB1 Suppresses Tumor-cell Intrinsic Immunogenicity

PRJNA656248 | ENA

Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identification

Systemic pan-tumor analyses may reveal the significance of common features implicated in cancer immunogenicity and patient survival. Here, we provide a comprehensive multi-omics data set for 32 patients across 25 tumor types for proteogenomic-based discovery of neoantigens. By using an optimized com...

ORGANISM(S): Homo sapiens (Human)

2023-05-16 | PXD037655 | Pride

Proteogenomics Neoantigens Human tumor Hla class i immunopeptidomics

Restoring Tumor Immunogenicity with Dendritic Cell Reprogramming

Immune evasion is an important hallmark of cancer ensured by diverse strategies, including immunosuppression and downregulation of antigen presentation. Here, to restore immunogenicity of cancer cells, we employed the minimal gene regulatory network of highly immunogenic type 1 conventional dendriti...

ORGANISM(S): Mus musculus (Mouse)

2023-10-24 | PXD039789 | Pride

Cancer antigens Cell reprogramming Immunopeptidomics Antigen presentation

Previous page
1 / 292
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 292
Next page

Sort by:

Relevance

Page size

2918 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

UNIPROT ID/AC

First Public Date

Modelling Approach

Study status

Lab affiliation

Tags

Keyword

IsPrivate

Submitter Keywords

Classification

Study type

Release Date

Location

OmicsDI is part of the ELIXIR infrastructure

Tweets